Skip to main content
SpringerLink
Log in

Recommendations for the Management of CML in the Era of Second-Generation TKIs

  • Chapter
Molecular Pathogenesis and Treatment of Chronic Myelogenous Leukemia

  • 710 Accesses

Abstract

Although imatinib 400 mg per day still represents the basic treatment for chronic myeloid leukemia (CML), the introduction of the second-generation tyrosine kinase inhibitors (TKIs) nilotinib and dasatinib and their subsequent registration as potential first- or second-line therapies are offering more options for the treatment of the CML patients. With respect to imatinib, nilotinib and dasatinib appear to offer some advantages in terms of efficacy as first-line treatment for newly diagnosed CML patients, like the capacity to induce very fast and deep molecular responses (MR4 and MR4.5) as well as to prevent part of the early progressions to AP/BC that may occur during the first two–three years from diagnosis. However their use has been associated with increased long-term toxicity, in particular in some groups of patients, and their high cost may represent a limitation to their use in countries where generic imatinib is or will soon become available. Potential long-term toxicity and a higher cost with respect to imatinib are also the factors that may influence the decision of the clinicians to switch the therapy to the use of a second-generation TKI in the cases showing a nonoptimal response to imatinib. All these elements are now animating an intense debate among hematologists on which could be the best therapeutic options to be used as first- and/or second-line therapies in the clinical management of CML patients.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Gambacorti-Passerini C, Antolini L, Mahon FX, et al. Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. J Natl Cancer Inst. 2011;103:553–61.

    Article  CAS  PubMed  Google Scholar 

  2. Kantarjian H, O’Brien S, Shan J, et al. Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions? Cancer. 2008;112:837–45.

    Article  PubMed  Google Scholar 

  3. Marin D, Milojkovic D, Olavarria E, et al. European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. Blood. 2008;112:4437–44.

    Article  CAS  PubMed  Google Scholar 

  4. Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122:872–84.

    Article  CAS  PubMed  Google Scholar 

  5. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ®) Chronic myelogenous leukemia Version 3. NCCN.org 2014.

    Google Scholar 

  6. Hughes T, Deininger M, Hochhaus A, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood. 2006;108:28–37.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  7. Muller MC, Saglio G, Lin F, et al. An international study to standardize the detection and quantitation of BCR-ABL transcripts from stabilized peripheral blood preparations by quantitative RT-PCR. Haematologica. 2007;92:970–3.

    Article  PubMed  Google Scholar 

  8. Cross NC, White HE, Muller MC, Saglio G, Hochhaus A. Standardized definitions of molecular response in chronic myeloid leukemia. Leukemia. 2012;26:2172–5.

    Article  CAS  PubMed  Google Scholar 

  9. Jabbour E, Kantarjian H, O’Brien S, et al. The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors. Blood. 2011;118:4541–6; quiz 759.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  10. Hanfstein B, Muller MC, Hehlmann R, et al. Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia. 2012;26(9):2096–102.

    Article  CAS  PubMed  Google Scholar 

  11. Hehlmann R, Muller MC, Lauseker M, et al. Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV. J Clin Oncol. 2014;32:415–23.

    Article  PubMed  Google Scholar 

  12. Mahon FX, Rea D, Guilhot J, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010;11:1029–35.

    Article  CAS  PubMed  Google Scholar 

  13. Ross DM, Branford S, Seymour JF, et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood. 2013;122:515–22.

    Article  CAS  PubMed  Google Scholar 

  14. Milojkovic D, Ibrahim AR, Foroni L, et al. Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with imatinib. ASH Annu Meet Abstr. 2011;118:1680.

    Google Scholar 

  15. Hughes TP, Saglio G, Kantarjian HM, et al. Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib. Blood. 2014;123:1353–60.

    Article  CAS  PubMed  Google Scholar 

  16. Jabbour E, Kantarjian HM, Saglio G, et al. Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). Blood. 2014;123:494–500.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  17. O’Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348:994–1004.

    Article  PubMed  Google Scholar 

  18. Goldman JM. Chronic myeloid leukemia: a historical perspective. Semin Hematol. 2010;47:302–11.

    Article  CAS  PubMed  Google Scholar 

  19. Hughes TP, Hochhaus A, Branford S, et al. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood. 2010;116:3758–65.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  20. Hehlmann R, Lauseker M, Jung-Munkwitz S, et al. Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-alpha in newly diagnosed chronic myeloid leukemia. J Clin Oncol Official J Am Soc Clin Oncol. 2011;29:1634–42.

    Article  CAS  Google Scholar 

  21. De Lavallade H, Apperley JF, Khorashad JS, et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol. 2008;26:3358–63.

    Article  PubMed  Google Scholar 

  22. Kantarjian H, O’Brien S, Jabbour E, et al. Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. Blood. 2012;119:1981–7.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  23. Hehlmann R, Saussele S. Treatment of chronic myeloid leukemia in blast crisis. Haematologica. 2008;93:1765–9.

    Article  CAS  PubMed  Google Scholar 

  24. Bolton-Gillespie E, Schemionek M, Klein HU, et al. Genomic instability may originate from imatinib-refractory chronic myeloid leukemia stem cells. Blood. 2013;121:4175–83.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  25. Shah NP, Guilhot F, Cortes JE, et al. Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study. Blood. 2014;123:2317–24.

    Article  CAS  PubMed  Google Scholar 

  26. Le Coutre PD, Giles FJ, Pinilla-Ibarz J, et al. Nilotinib in imatinib-resistant or -intolerant patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP): 48-month follow-up results of a phase 2 study. ASH Annu Meet Abstr. 2011;118:3770.

    Google Scholar 

  27. Sokal JE, Cox EB, Baccarani M, et al. Prognostic discrimination in “good-risk” chronic granulocytic leukemia. Blood. 1984;63:789–99.

    CAS  PubMed  Google Scholar 

  28. Hasford J, Pfirrmann M, Hehlmann R, et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst. 1998;90:850–8.

    Article  CAS  PubMed  Google Scholar 

  29. Hasford J, Baccarani M, Hoffmann V, et al. Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. Blood. 2011;118:686–92.

    Article  CAS  PubMed  Google Scholar 

  30. Kantarjian H, O’Brien S, Jabbour E, et al. Impact of treatment End point definitions on perceived differences in long-term outcome with tyrosine kinase inhibitor therapy in chronic myeloid leukemia. J Clin Oncol. 2011;29(23):3173–8.

    Article  PubMed  Google Scholar 

  31. Guilhot J, Baccarani M, Clark RE, et al. Definitions, methodological, and statistical issues for phase III clinical trials in chronic myeloid leukemia: a proposal by the European LeukemiaNet. Blood. 2012;119(25):5963–71.

    Article  CAS  PubMed  Google Scholar 

  32. Giles FJ. New directions in the treatment of imatinib failure and/or resistance. Semin Hematol. 2009;46:S27–33.

    Article  CAS  PubMed  Google Scholar 

  33. Doggrell SA. BMS-354825: a novel drug with potential for the treatment of imatinib-resistant chronic myeloid leukaemia. Expert Opin Investig Drugs. 2005;14:89–91.

    Article  PubMed  Google Scholar 

  34. Weisberg E, Manley P, Mestan J, Cowan-Jacob S, Ray A, Griffin JD. AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL. Br J Cancer. 2006;94:1765–9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  35. Keller G, Schafhausen P, Brummendorf TH. Bosutinib: a dual SRC/ABL kinase inhibitor for the treatment of chronic myeloid leukemia. Expert Rev Hematol. 2009;2:489–97.

    Article  CAS  PubMed  Google Scholar 

  36. Jabbour E, Branford S, Saglio G, Jones D, Cortes JE, Kantarjian HM. Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia. Cancer. 2010;117(9):1800–11.

    Article  PubMed Central  PubMed  Google Scholar 

  37. Rosti G, Palandri F, Castagnetti F, et al. Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia. Blood. 2009;114:4933–8.

    Article  CAS  PubMed  Google Scholar 

  38. Cortes JE, Jones D, O’Brien S, et al. Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase. J Clin Oncol. 2010;28:392–7.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  39. Cortes JE, Jones D, O’Brien S, et al. Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia. J Clin Oncol. 2010;28:398–404.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  40. Saglio G, Kim DW, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010;362:2251–9.

    Article  CAS  PubMed  Google Scholar 

  41. Saglio G, Hughes TP, Clark RE, Nakamae H, Kim DW, Jootar S, Etienne G, Flinn I, Lipton JH, Pasquini R, Moiraghi B, Kemp C, Fan X, Menssen HD, Kantarjian HM, Larson RA. ENESTnd Update: Nilotinib (NIL) Vs Imatinib (IM) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) and the impact of Early Molecular Response (EMR) and Sokal risk at diagnosis on long-term outcomes. Blood. 2013;122:92.

    Google Scholar 

  42. Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010;362:2260–70.

    Article  CAS  PubMed  Google Scholar 

  43. Cortes J SG, Shah N, et al. Final study results of DASISION (Dasatinib versus Imatinib in newly diagnosed chronic Myeloid Leukemia in Chronic Phase CML). European School of Hematology meeting. Philadelphia, 2014.

    Google Scholar 

  44. Radich JP, Kopecky KJ, Appelbaum FR, et al. A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia. Blood. 2012;120:3898–905.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  45. Cortes JE, Kim DW, Kantarjian HM, et al. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial. J Clin Oncol. 2012;30:3486–92.

    Article  CAS  PubMed  Google Scholar 

  46. Giles FJ, Mauro MJ, Hong F, et al. Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis. Leukemia. 2013;27:1310–5.

    Article  CAS  PubMed  Google Scholar 

  47. Marin D, Ibrahim AR, Lucas C, et al. Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Clin Oncol. 2012;30:232–8.

    Article  CAS  PubMed  Google Scholar 

  48. Bradord S, Yeung DT, Parker WT, et al. Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline. Blood. 2014;124:511–8.

    Article  Google Scholar 

  49. Hanfstein B, Shlyakhto V, Lauseker M, et al. Velocity of early BCR-ABL1 transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib. Leukemia. 2014;28:1988–92.

    Article  CAS  PubMed  Google Scholar 

  50. Fava C, Rege-Cambrin G, Saglio G. The choice of first-line chronic myelogenous leukemia treatment. Ann Hematol. 2015;94 Suppl 2:123–31.

    Article  PubMed Central  CAS  Google Scholar 

  51. Morotti A, Fava C, Saglio G. Milestones and monitoring. Curr Hematol Malig Rep. 2015;10(2):167–72.

    Article  PubMed Central  PubMed  Google Scholar 

Download references

Acknowledgments

This work has been supported by grants from Associazione Italiana contro le Leucemie (AIL) and Associazione Italiana per la Ricerca sul Cancro (AIRC).

Author information

Authors and Affiliations

  1. Division of Hematology and Internal Medicine, Department of Clinical and Biological Sciences, University of Turin, “San Luigi Gonzaga”, University Hospital, Orbassano, Turin, 10043, Italy

    Alessandro Morotti, Carmen Fava & Giuseppe Saglio MD

Authors
  1. Alessandro Morotti
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Carmen Fava
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Giuseppe Saglio MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Giuseppe Saglio MD .

Editor information

Editors and Affiliations

  1. Department of Hematology, Saitama Medical Center Saitama MEdical University, Kawagoe, Saitama, Japan

    Masahiro Kizaki

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer Japan

About this chapter

Cite this chapter

Morotti, A., Fava, C., Saglio, G. (2016). Recommendations for the Management of CML in the Era of Second-Generation TKIs. In: Kizaki, M. (eds) Molecular Pathogenesis and Treatment of Chronic Myelogenous Leukemia. Springer, Tokyo. https://doi.org/10.1007/978-4-431-55714-2_8

Download citation

  • DOI: https://doi.org/10.1007/978-4-431-55714-2_8

  • Publisher Name: Springer, Tokyo

  • Print ISBN: 978-4-431-55713-5

  • Online ISBN: 978-4-431-55714-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation